Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate

International Journal of Nanomedicine

Volumn 1, Issue 4, 2006, Pages 375-383

  Chipman, Stewart D ^a   Oldham, Fred B ^a   Pezzoni, Gabriella ^a   Singer, Jack W ^a  

^a Cell Therapeutics Inc   (United States)

Author keywords

Estradiol; Lung neoplasms; Paclitaxel; Poly L glutamic acid

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG CARRIER; ESTRADIOL; PACLITAXEL; POLYGLUTAMIC ACID; TUBULIN;

ANIMAL; APOPTOSIS; CHEMISTRY; DRUG EFFECT; HUMAN; MACROMOLECULE; METABOLISM; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; DRUG CARRIERS; ESTRADIOL; HUMANS; MACROMOLECULAR SUBSTANCES; NEOPLASMS; PACLITAXEL; POLYGLUTAMIC ACID; TUBULIN;

EID: 34548626932     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/nano.2006.1.4.375     Document Type: Review

References (51)

1. Achkar C, Gong QM, Frankfater A, et al. 1990. Differences in targeting and secretion of cathepsins B and L by BALB/3T3 fibroblasts and Moloney murine sarcoma virus-transformed BALB/3T3 fibroblasts. J Biol Chem, 265:13650-4.
2. Albain KS, Crowley JJ, Leblanc M, et al. 1991. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol, 9:1618-26.
3. Bala I, Hariharan S, Kumar MN 2004. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst, 21:387-422.
4. Bernareggi A, Oldham F, Baker B, et al. 2005. XYOTAX™ (paclitaxel poliglumex, PPX): tumor accumulation and prolonged exposure to paclitaxel. 11th World Congress on Lung Cancer. Barcelona, Spain.Bhalla KN. 2003. Microtubule-targeted anticancer agents and apoptosis. Oncogene, 22:9075-86.
5. Blackhall FH, Bhosle J, Thatcher N. 2005. Chemotherapy for advanced non-small cell lung cancer patients with performance status 2. Curr Opin Oncol, 17:135-9.
6. Cavallo-Medved D, Mai J, Dosescu J, et al. 2005, Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J Cell Sci, 118:1493-503.
7. Crinò L, Migliorino M. 2002, A phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer (NSCLC): impact of PS = 2 vs 0 or 1 and age >70 vs <70 on chemotherapy outcome. Proc Am Soc Clin Oncol, 21:315a.
8. Deroo BJ, Korach KS. 2006. Estrogen receptors and human disease. J Clin Invest, 116, 561-70.
9. Duncan R. 1992. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs, 3:175-210.
10. Duncan R. 2003. The dawning era of polymer therapeutics. Nat Rev Drug Discov, 2:347-60.
11. Edwards DP. 2005. Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol, 67:335-76.
12. Frasor J, Danes JM, Komm B, et al. 2003. Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology, 144:4562-74.
13. Gelderblom H, Verweij J, Nooter K, et al. 2001. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer, 37:1590-8.
14. Gerlowski LE, Jain RK. 1986. Microvascular permeability of normal and neoplastic tissues. Microvasc Res, 31:288-305.
15. Greish K, Fang J, Inutsuka T, et al. 2003. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet, 42:1089-105.
16. Gueritte-Voegelein F, Guenard D, Lavelle F, et al. 1991. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem, 34:992-8.
17. Kos J, Sekirnik A, Premzl A, et al. 2005. Carboxypeptidases cathepsins X and B display distinct protein profile in human cells and tissues. Exp Cell Res, 306:103-13.
18. Kumar GN, Walle UK, Bhalla KN. et al. 1993. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol, 80:337-44.
19. Langer CJ, Socinski MA, Ross H, et al. 2005. Paclitaxel poliglumex (PPX)/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): A phase III study. J Clin Oncol, ASCO Annual Meeting Proceedings, 23:7011.
20. Langer R. 1998. Drug delivery and targeting. Nature, 392:5-10.
21. Linebaugh BE, Sameni M, Day NA, et al. 1999. Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass. Eur J Biochem, 264:100-9.
22. Liu Y, Inoue M, Sobue T. et al. 2005. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer, 117:662-6.
23. Manfredi JJ, Parness J, Horwitz SB. 1982. Taxol binds to cellular microtubules. J Cell Biol, 94:688-96.
24. Markman M. 2003. Managing taxane toxicities. Support Care Cancer, 11:144-7.
25. Massaro D, Massaro GD. 2004. Estrogen regulates pulmonary alveolar formation, loss, and regeneration in mice. Am J Physiol Lung Cell Mol Physiol, 287:L1154-9.
26. Massaro D, Massaro GD. 2006. Estrogen receptor regulation of pulmonary alveolar dimensions: alveolar sexual dimorphism in mice. Am J Physiol Lung Cell Mol Physiol, 290:L866-70.
27. Massaro GD, Mortola JP, Massaro D. 1996. Estrogen modulates the dimensions of the lung's gas-exchange surface area and alveoli in female rats. Am J Physiol, 270:L110-4.
28. Matsumura Y, Maeda H. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res, 46:6387-92.
29. O'Byrne KJ. 2005a. Paclitaxel poliglumex vs. gemcitabine or vinorelbine for the treatment of performance status (PS) 2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): the STELLAR 4 phase III study. Eur J Cancer Suppl, 3:324.
30. O'Byrne KJ. 2005b. Paclitaxel poliglumex vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): the STELLAR 2 phase III study. Eur J Cancer Suppl, 3:5.
31. Patel JD. 2005. Lung cancer in women. J Clin Oncol, 23:3212-8.
32. Patrone C, Cassel TN, Pettersson K, et al. 2003. Regulation of postnatal lung development and homeostasis by estrogen receptor beta. Mol Cell Biol, 23:8542-52.
33. Phiel KL, Henderson RA, Adelman SJ, et al. 2005. Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol Lett, 97:107-13.
34. Poole AR, Tiltman KJ, Recklies AD, et al. 1978. Differences in secretion of the proteinase cathepsin B at the edges of human breast carcinomas and fibroadenomas. Nature, 273:545-7.
35. Premzl A, Zavasnik-Bergant V, Turk V, et al. 2003. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp Cell Res, 283:206-14.
36. Roberts WG, Palade GE. 1997. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res, 57:765-72.
37. Roshy S, Sloane BF, Moin K. 2003. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev, 22:271-86.
38. Ross H, Bonomi P, Langer C, et al. 2006. Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaïve pts with advanced NSCLC and poor performance status (PS2). J Clin Oncol, ASCO Annual Meeting Proceedings, 24:7039.
39. Rowinsky EK, Donehower RC. 1995. Paclitaxel (taxol). N Engl J Med, 332:1004-14.
40. Sameni M, Elliott E, Ziegler G, et al. 1995. Cathepsin B and D are localized at the surface of human breast cancer cells. Pathol Oncol Res, 1:43-53.
41. Seidman AD. 2005. "Will weekly work"? Seems to be so. J Clin Oncol, 23:5873-4.
42. Shaffer SA, Lee-Baker C, Kennedy, K., et al. 2007. In vitro and in vivo metabolism of paclitaxel poliglumex: Identification of metabolites and active proteases. Cancer Chemother Pharmacol. In press.
43. Singer JW, Shaffer S, Baker B, et al. 2005. Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anticancer Drugs, 16:243-54.
44. Sloane BF, Moin K, Sameni M, et al. 1994. Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J Cell Sci, 107:373-84.
45. Sonnichsen DS, Relling MV. 1994. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet, 27:256-69.
46. Spiess E, Bruning A, Gack S, et al. 1994. Cathepsin B activity in human lung tumor cell lines: ultrastructural localization, pH sensitivity, and inhibitor status at the cellular level. J Histochem Cytochem, 42:917-29.
47. Sweeney CJ, Zhu J, Sandler, et al. 2001. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer, 92:2639-47.
48. Szpaderska AM, Frankfater A. 2001. An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res, 61:3493-500.
49. Thomas L, Doyle LA, Edelman MJ. 2005. Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest, 128:370-81.
50. Wu CT, Chang YL, Shih JY, et al. 2005. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg, 130:979-86.
51. Yan S, Sloane BF. 2003. Molecular regulation of human cathepsin B: implication in pathologies. Biol Chem, 384:845-54.